MSD Wins All 14 Challenges at U.S. Patent Board
German Higher Regional Court Lifts Sales Injunction
Halozyme: "We Will Immediately File an Infringement Lawsuit in Germany"

U.S. Merck (MSD) has scored back-to-back victories in the United States and Germany in its patent dispute with Halozyme over the subcutaneous (SC) formulation of Keytruda. In the United States, a series of Halozyme patents were deemed invalid, while in Germany, a court order that had blocked sales was overturned. Halozyme, however, prevailed in the Netherlands, and appeals and proceedings on the merits are still pending.


On November 18 (local time), the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office ruled in two post-grant review (PGR) proceedings brought by MSD against Halozyme patents that all challenged claims were unpatentable. This means that all 14 PGR proceedings requested by MSD in which review was instituted ended with findings against the patentability of Halozyme patents. A day later, on November 19 (local time), the Higher Regional Court of Munich overturned a preliminary injunction barring sales of Keytruda SC that had been issued by a lower court on December 1 last year.


The dispute concerns Halozyme's MDASE patent family. The patents cover variants of hyaluronidase (PH20), an enzyme used in subcutaneous injections, with altered amino acids. Keytruda SC contains ALT-B4, a hyaluronidase developed by South Korean company Alteogen. Halozyme has argued that the enzyme infringes its MDASE patents. The outcome of the dispute is therefore directly linked to royalty revenue Alteogen receives for licensing its technology to MSD.


Product image of Keytruda Qlex, a subcutaneous (SC) formulation of Keytruda. MSD

Product image of Keytruda Qlex, a subcutaneous (SC) formulation of Keytruda. MSD

View original image

U.S. Patent Board Rejects Patentability of All 14 Halozyme Patents Challenged by MSD


The PTAB found that Halozyme had experimentally confirmed the effectiveness of only variants in which a single amino acid had been changed. Nevertheless, Halozyme claimed rights over numerous variants with multiple sites altered simultaneously. The basis for the invalidity ruling was that the patent specifications did not support the full scope of the claims. The two patents addressed in the latest decisions also cover variants with a single amino acid change as well as additional modifications at up to around 20 sites.


The PTAB's invalidity rulings have weakened the basis for Halozyme's infringement lawsuit in the United States. MSD began filing PGR petitions seeking to invalidate Halozyme patents in November 2024, before Keytruda SC's U.S. launch. In April 2025, Halozyme responded by suing in federal court in New Jersey, alleging that Keytruda SC, marketed in the United States as Keytruda Qlex, infringed 15 of its MDASE patents. The two patents found invalid in the latest decisions are among those included in the lawsuit.


Halozyme is challenging the PTAB's decisions. It appealed four earlier invalidity decisions to the U.S. Court of Appeals for the Federal Circuit (CAFC). The patents will lose their effect definitively only if the invalidity rulings are upheld on appeal.


Europe Sees Diverging Rulings by Country: Germany Lifts Injunction, Netherlands Finds Infringement


Litigation is ongoing in various European countries. Halozyme immediately pushed back after the Higher Regional Court of Munich lifted the preliminary injunction barring sales of Keytruda SC. In a press release on November 19, Halozyme Chief Legal Officer (CLO) Mark Snyder said, "We disagree with the decision," adding, "We will immediately file an infringement lawsuit in Germany seeking a permanent injunction against MSD."


Halozyme prevailed in a patent infringement lawsuit in the Netherlands. Last month, a Dutch patent court ruled that Keytruda SC infringed Halozyme's MDASE patent. As a result, the MSD affiliate that holds the European marketing authorization is unable to manufacture or sell Keytruda SC in eight countries, including the Netherlands, France and Italy. In the United Kingdom, a trial will begin at the end of this month to determine the validity of another MDASE patent and whether it has been infringed. Halozyme said the MDASE patents are separate from licenses for its core subcutaneous drug delivery technology, ENHANZE, and that the outcome of the dispute will not affect ENHANZE revenue.



MSD launched Keytruda SC in preparation for the expiration in 2028 of key patents on Keytruda for intravenous (IV) use. Third-quarter sales were $830 million (approximately KRW 1.1084 trillion), accounting for about 10% of total sales of Keytruda products. Alteogen signed a technology licensing agreement with MSD for ALT-B4 in 2020. It is eligible to receive up to $1 billion in milestone payments depending on sales targets, and will receive royalties of 2% of net sales after all milestone payments have been made.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing